Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker

Official Title

A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker

Summary:

Studies have shown that the study drug, pembrolizumab, works by helping the immune system. In this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells to die. Compared to standard treatments, pembrolizumab seems to lengthen the time patients lived overall and the time without their cancer getting worse.

Trial Description

Primary Outcome:

  • Measurement of tumour texture by CT scan
Secondary Outcome:
  • Measure tumour texture by CT for correlation with time to disease progression
  • Duration of response rate assessed by CT scan
  • Overall survival
  • Compare cost per quality adjusted life years between pembrolizumab and dacarbazine by collecting information from patients on health care resources used
  • Compare cost per quality adjusted life years between pembrolizumab and ipilimumab by collecting information from patients on health care resources used
  • Number and severity of adverse events using CTCAE v4
  • Overall response rate assessed by CT scan
The main purpose of this study is to find out if a type of CT (computed topography) scan can help to know if pembrolizumab is working. This CT scan (called Texture Analysis) looks at the tumour in fine detail. The use of this type of CT scan has not been studied in patients with metastatic melanoma. Investigators want to see if this CT scan will show if some patients being treated with pembrolizumab respond better than others. One of the other purposes is to compare the costs within this trial to costs of the standard of care.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society